- Home
- PRPO vs YI Comparison
PRPO vs YI Comparison
Compare PRPO & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- YI
- Stock Information
- Founded
- PRPO N/A
- YI 2010
- Country
- PRPO United States
- YI China
- Employees
- PRPO N/A
- YI N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- PRPO Industrials
- YI Consumer Staples
- Exchange
- PRPO Nasdaq
- YI Nasdaq
- Market Cap
- PRPO 32.4M
- YI 38.1M
- IPO Year
- PRPO N/A
- YI N/A
- Fundamental
- Price
- PRPO $20.50
- YI $3.88
- Analyst Decision
- PRPO
- YI
- Analyst Count
- PRPO 0
- YI 0
- Target Price
- PRPO N/A
- YI N/A
- AVG Volume (30 Days)
- PRPO 11.3K
- YI 7.9K
- Earning Date
- PRPO 11-17-2025
- YI 12-05-2025
- Dividend Yield
- PRPO N/A
- YI N/A
- EPS Growth
- PRPO N/A
- YI N/A
- EPS
- PRPO N/A
- YI N/A
- Revenue
- PRPO $21,242,000.00
- YI $1,979,883,442.00
- Revenue This Year
- PRPO N/A
- YI N/A
- Revenue Next Year
- PRPO N/A
- YI N/A
- P/E Ratio
- PRPO N/A
- YI N/A
- Revenue Growth
- PRPO 27.05
- YI N/A
- 52 Week Low
- PRPO $3.90
- YI $3.85
- 52 Week High
- PRPO $22.38
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- PRPO 51.49
- YI 27.42
- Support Level
- PRPO $19.00
- YI $3.87
- Resistance Level
- PRPO $21.00
- YI $4.17
- Average True Range (ATR)
- PRPO 1.05
- YI 0.16
- MACD
- PRPO -0.16
- YI 0.00
- Stochastic Oscillator
- PRPO 27.44
- YI 18.42
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.